Skip to main content
    W

    Whitehawk Therapeutics, Inc. (WHWK)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.01
    -0.05 (-1.63%)

    Market Cap: $180.57M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Whitehawk Therapeutics, Inc. (WHWK) Earnings: Report Dates and Results

    Updated Nov 9, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Whitehawk Therapeutics (WHWK) is expected to report earnings on Mar 10, 2027. In the quarter ended Sep 30, 2026, Whitehawk Therapeutics reported EPS of -$0.23, above the -$0.24 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    58%(15/26)
    Avg Surprise
    -13.46%
    Streak
    4 Q

    Upcoming Estimates

    Reports Mar 10, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.22
    Range-$0.25 - -$0.14
    11 analysts
    Revenue Consensus
    N/A
    RangeN/A
    11 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.23
    Range-$0.24 - -$0.22
    2 analysts
    EPS Revisions
    2
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.24+2.1%
    60d ago-$0.24+2.1%
    30d ago-$0.24+2.1%
    7d ago-$0.24+2.1%
    Current-$0.23
    Revenue Consensus
    N/A
    RangeN/A
    3 analysts

    Next Report

    WHWK has an expected report date of Mar 10, 2027.

    WHWK Earnings Call

    The latest WHWK earnings call transcript on file is labeled 2024Q4.

    Read the 2024Q4 transcript

    Earnings History

    Of the 26 quarters below that had an estimate, WHWK beat 15, missed 8 and matched 3. The widest gap in the table came in the quarter ended Jun 30, 2025, when EPS landed 255.10% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.23-$0.24-$0.27 - -$0.21+4.17%BeatN/A42 up, 0 downNov 9, 2026N/A
    Jun 30, 2026-$0.20-$0.30N/A+33.33%BeatN/A4N/AAug 6, 2026N/A
    Mar 31, 2026-$0.32-$0.33-$0.36 - -$0.29+3.03%BeatN/A30 up, 2 downMay 7, 2026N/A
    Dec 31, 2025-$0.34-$0.69N/A+50.74%BeatN/A20 up, 1 downMar 12, 2026N/A
    Sep 30, 2025-$0.25-$0.22N/A-13.64%MissN/A13 up, 0 downNov 6, 2025N/A
    Jun 30, 2025-$0.76$0.49N/A-255.10%MissN/A13 up, 0 downAug 7, 2025N/A
    Mar 31, 2025-$0.36-$0.23N/A-56.52%MissN/AN/AN/AMay 8, 2025$7.14M
    Dec 31, 2024-$0.67-$0.21N/A-219.05%MissN/AN/AN/AMar 18, 2025$7.24M
    Sep 30, 2024-$0.37-$0.47N/A+21.28%BeatN/AN/AN/ANov 6, 2024$7.21M
    Jun 30, 2024-$0.54-$0.64N/A+15.63%BeatN/AN/AN/AAug 7, 2024$6.18M
    Mar 31, 2024-$0.68-$0.62N/A-9.68%MissN/AN/AN/AMay 8, 2024$5.35M
    Dec 31, 2023-$0.60-$0.65N/A+7.69%BeatN/AN/AN/AMar 13, 2024$6.33M
    Sep 30, 2023-$0.60-$0.73N/A+17.81%BeatN/AN/AN/ANov 8, 2023$5.96M
    Jun 30, 2023-$0.67-$0.60N/A-11.67%MissN/AN/AN/AAug 9, 2023$6.20M
    Mar 31, 2023-$0.57-$0.57N/A0.00%In lineN/AN/AN/AMay 10, 2023$5.87M
    Dec 31, 2022-$0.48-$0.72N/A+33.33%BeatN/AN/AN/AMar 29, 2023$5.23M
    Sep 30, 2022-$0.68-$0.75N/A+9.33%BeatN/AN/AN/ANov 9, 2022$4.25M
    Jun 30, 2022-$0.69-$0.73N/A+5.48%BeatN/AN/AN/AAug 10, 2022$3.44M
    Mar 31, 2022-$0.66-$0.68N/A+2.94%BeatN/AN/AN/AMay 12, 2022$2.31M
    Dec 31, 2021-$0.77-$0.77N/A0.00%In lineN/AN/AN/AMar 17, 2022$1.00M
    Sep 30, 2021-$1.42-$0.73N/A-94.52%MissN/AN/AN/ANov 10, 2021N/A
    Jun 30, 2021-$1.35-$6.00N/A+77.50%Beat-687.0%N/AN/AAug 11, 2021N/A
    Mar 31, 2021-$0.09-$0.09N/A0.00%In lineN/AN/AN/AMay 17, 2021$120000
    Dec 31, 2020-$0.10-$0.14N/A+28.57%BeatN/AN/AN/AMar 11, 2021N/A
    Sep 30, 2020-$0.12-$0.14N/A+14.29%BeatN/AN/AN/ANov 10, 2020$231000
    Jun 30, 2020$0.23$0.27N/A-14.81%MissN/AN/AN/AAug 12, 2020$15.00M
    Mar 31, 2020-$1.45N/AN/AN/AN/AN/AN/AN/AMay 7, 2020N/A
    Dec 31, 2019-$1.64N/AN/AN/AN/AN/AN/AN/AMar 16, 2020N/A
    Sep 30, 2019-$1.72N/AN/AN/AN/A-140.7%N/AN/ANov 7, 2019N/A
    Jun 30, 2019-$2.10N/AN/AN/AN/AN/AN/AN/AAug 8, 2019N/A
    Mar 31, 2019-$3.14N/AN/AN/AN/AN/AN/AN/AMay 9, 2019N/A
    Dec 31, 2018-$3.15N/AN/AN/AN/AN/AN/AN/AMar 5, 2019$2144
    Sep 30, 2018$4.23N/AN/AN/AN/AN/AN/AN/ANov 7, 2018$18.82M
    Jun 30, 2018-$3.29N/AN/AN/AN/AN/AN/AN/AAug 14, 2018$1.33M
    Mar 31, 2018-$4.12N/AN/AN/AN/AN/AN/AN/AMay 15, 2018N/A
    Dec 31, 2017-$3.47N/AN/AN/AN/AN/AN/AN/AMar 13, 2018N/A
    Sep 30, 2017-$2.59N/AN/AN/AN/AN/AN/AN/ANov 29, 2017N/A
    Last 37 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.71, after -$2.26 the year before. It was -$6.06 for the year ended Dec 31, 2017, the oldest of the 9 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.71N/A
    Dec 31, 2024-$2.26N/A
    Dec 31, 2023-$2.44N/A
    Dec 31, 2022-$2.51N/A
    Dec 31, 2021-$3.63N/A
    Dec 31, 2020-$1.44N/A
    Dec 31, 2019-$8.60N/A
    Dec 31, 2018-$6.33N/A
    Dec 31, 2017-$6.06N/A

    Earnings Calls

    The 2 most recent earnings calls are listed below; the latest, 2024Q4 for the period ended Dec 31, 2024, runs about 2,900 words across 7 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2024Q4Dec 31, 20242,9477
    2024Q2Jun 30, 20245,49210

    2024Q4 Earnings Call

    Opening remarks

    Audrey Gross Head of Corporate Communications Thank you. Good morning, and welcome to the Whitehawk Therapeutics conference call. We will be presenting slides as part of the live webcast of this call. Such slides will be posted on the Investor News page of the Whitehawk Therapeutics website at whitehawktx.com following the conference call. A reminder that statements made on the call today will include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including those set forth in the Risk Factors section of our annual and quarterly filings with the Securities and Exchange Commission, which can be found at www.sec.gov or on our website at whitehawktx.com. In addition, any forward-looking statements made on this call represent our views only as of today, March 19, 2025, and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements. On the call today is Dr. Dave Lennon, our President and CEO; Scott Giacobello, our CFO; and Dr. David Dornan, our newly appointed CSO. Today, we will introduce Whitehawk Therapeutics and provide an overview of Q4 and full year 2024 financial results before turning the line open for questions. I'll now turn the call over to Dave. Dave?

    Dave Lennon President and CEO Thank you, Audrey. Hello, everyone. Good morning, and thank you for being here. I'm Dave Lennon, the President and CEO of the newly launched Whitehawk Therapeutics. We are very excited about our transition from Aadi Biosciences to Whitehawk. I am eager to share our vision, strategy, and the opportunities we have to make a significant impact for patients through our advanced ADC portfolio. In December, we announced several strategic transactions, including the in-licensing of three ADCs from Wuxi Biologics, the divestiture of FYARRO to Kaken Pharmaceuticals, and a $100 million private investment that received approval in a special meeting of stockholders last month. As we move forward, Aadi Biosciences is now reorganized into two entities. After Kaken's acquisition of Aadi's subsidiary, they will now own the Aadi name, trademark, and the FYARRO business. Today, the Aadi Parent Company rebrands as Whitehawk Therapeutics, solidifying our focus on ADC development. While we remain grounded in our roots of using technology to enhance precision oncology therapies, Whitehawk presents several new distinctions. Aadi was previously centered on mTOR inhibition within rare cancer settings and was based on the foundation of a single commercial product. In contrast, Whitehawk is dedicated to rapidly advancing a multi-asset portfolio of cutting-edge ADC therapies designed to deliver meaningful improvements across various cancer populations.

    Frequently Asked Questions About WHWK

    When is Whitehawk Therapeutics's next earnings date?

    Whitehawk Therapeutics's next earnings report is expected for Mar 10, 2027.

    Did WHWK beat earnings estimates last quarter?

    Yes. Whitehawk Therapeutics reported EPS of -$0.23 for the quarter ended Sep 30, 2026, above the -$0.24 estimate, a 4.17% surprise.

    What EPS do analysts expect from WHWK next quarter?

    The consensus EPS estimate for Whitehawk Therapeutics for the quarter ending Dec 31, 2026 is -$0.22 from 11 analysts, with estimates from -$0.25 to -$0.14.

    How often does WHWK beat earnings estimates?

    Whitehawk Therapeutics beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -56.63%.